CO5601020A2 - OX-AZABICICLIC COMPOUNDS - Google Patents

OX-AZABICICLIC COMPOUNDS

Info

Publication number
CO5601020A2
CO5601020A2 CO04082792A CO04082792A CO5601020A2 CO 5601020 A2 CO5601020 A2 CO 5601020A2 CO 04082792 A CO04082792 A CO 04082792A CO 04082792 A CO04082792 A CO 04082792A CO 5601020 A2 CO5601020 A2 CO 5601020A2
Authority
CO
Colombia
Prior art keywords
alkyl
group
hydrogen
independently
represent
Prior art date
Application number
CO04082792A
Other languages
Spanish (es)
Inventor
Bernard Gaudilliere
Henry Jacobelli
Catherine Kostlan
Jack Li
Yue Wen-Song
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CO5601020A2 publication Critical patent/CO5601020A2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/91Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

1.- Un compuesto seleccionado de aquellos de la fórmula (I):caracterizado porque:? X1, X2 y X3, independientemente uno de otro, representan un átomo de nitrógeno o un grupo -CR3 en donde R3 representa un grupo seleccionado de hidrógeno, alquilo (de C1-C6), amino, monoalquilamino (de C1-C6), dialquilamino (de C1-C6), hidroxi, alcoxi (de C1-C6) y halógeno, con la condición de que no más de dos de los grupos X1, X2 y X3 simultáneamente representen un átomo de nitrógeno,? G1 representa un grupo seleccionado de aquellos de lasfórmulas (i/a) e (i/b): en donde:- el átomo de carbono con el número 2 está unido al grupo N-R1 del anillo,- R4 y R5, idénticos o diferentes, independientemente uno de otro, representan un grupo seleccionado de hidrógeno, alquilo (de C1-C6), arilo, arilalquilo (de C1-C6), cicloalquilo, cicloalquilalquilo (de C1-C6), heteroarilo, heteroarilalquilo (de C1-C6), heterocicloalquilo, y heterocicloalquilalquilo (de C1-C6),- R4 representa un grupo seleccionado de: hidrógeno, trifluorometilo, OR7, NR7R8, en donde R7 y R8, idénticos o diferentes independientemente uno de otro, representan hidrógeno o alquilo (de C1-C6), alquilo (de C1-C6), alquenilo (de C2-C6), alquinilo (de C2-C6), arilo, arilalquilo (de C1-C6), cicloalquilalquilo (de C1-C6), heteroarilo, heteroarilalquilo (de C1-C6), heterocicloalquilo, y heterocicloalquilalquilo (de C1-C6), estos grupos son optativamente sustituidos por uno o más grupos, que pueden ser idénticos o diferentes independientemente uno de otro, seleccionados de halógeno, amino, monoalquilamino (de C1-C6), dialquilamino (de C1-C6), cada grupo alquilo es idéntico o diferente independientemente uno de otro, ...1.- A compound selected from those of the formula (I): characterized in that :? X1, X2 and X3, independently of each other, represent a nitrogen atom or a -CR3 group in which R3 represents a group selected from hydrogen, (C1-C6) alkyl, amino, monoalkylamino (from C1-C6), dialkylamino (from C1-C6), hydroxy, alkoxy (from C1-C6) and halogen, with the proviso that no more than two of the groups X1, X2 and X3 simultaneously represent a nitrogen atom ,? G1 represents a group selected from those of the formulas (i / a) and (i / b): where: - the carbon atom with the number 2 is attached to the N-R1 group of the ring, - R4 and R5, identical or different, independently of one another, represent a group selected from hydrogen, (C1-C6) alkyl, aryl, arylalkyl (from C1-C6), cycloalkyl, cycloalkylalkyl (from C1-C6), heteroaryl, heteroarylalkyl (from C1-C6 ), heterocycloalkyl, and heterocycloalkylalkyl (from C1-C6), - R4 represents a group selected from: hydrogen, trifluoromethyl, OR7, NR7R8, wherein R7 and R8, identical or different independently of each other, represent hydrogen or (C1-alkyl) -C6), (C1-C6) alkyl, alkenyl (from C2-C6), alkynyl (from C2-C6), aryl, arylalkyl (from C1-C6), cycloalkylalkyl (from C1-C6), heteroaryl, heteroarylalkyl ( of C1-C6), heterocycloalkyl, and heterocycloalkylalkyl (of C1-C6), these groups are optionally substituted by one or more groups, which may be identical or different independently from each other, selected from halogen, amino, monoalkylamino (from C1-C6), dialkylamino (from C1-C6), each alkyl group is identical or different independently from each other, ...

CO04082792A 2002-03-08 2004-08-25 OX-AZABICICLIC COMPOUNDS CO5601020A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/003240 WO2003076416A1 (en) 2002-03-08 2002-03-08 Oxo azabicyclic compounds

Publications (1)

Publication Number Publication Date
CO5601020A2 true CO5601020A2 (en) 2006-01-31

Family

ID=27798761

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04082792A CO5601020A2 (en) 2002-03-08 2004-08-25 OX-AZABICICLIC COMPOUNDS

Country Status (25)

Country Link
EP (1) EP1492775A2 (en)
JP (1) JP2005526070A (en)
KR (1) KR20040095270A (en)
CN (1) CN1738806A (en)
AP (1) AP2004003125A0 (en)
AR (1) AR039562A1 (en)
AU (2) AU2002249275A1 (en)
BR (1) BR0308280A (en)
CA (1) CA2478706A1 (en)
CO (1) CO5601020A2 (en)
EA (1) EA200401053A1 (en)
EC (1) ECSP045278A (en)
IL (1) IL163818A0 (en)
IS (1) IS7414A (en)
MA (1) MA27183A1 (en)
MX (1) MXPA04008681A (en)
NO (1) NO20044041L (en)
OA (1) OA12782A (en)
PA (1) PA8568501A1 (en)
PE (1) PE20031018A1 (en)
PL (1) PL372622A1 (en)
SV (1) SV2003001495A (en)
TN (1) TNSN04169A1 (en)
UY (1) UY27700A1 (en)
WO (2) WO2003076416A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (en) 2001-02-14 2002-09-30 Warner Lambert Co TRIAZOLO COMPOUNDS AS MMP INHIBITORS
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
CA2495293A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
PA8578101A1 (en) 2002-08-13 2004-05-07 Warner Lambert Co HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS
WO2004014384A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
CA2497656A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
EP1537098A1 (en) 2002-08-13 2005-06-08 Warner-Lambert Company LLC Monocyclic derivatives as matrix metalloproteinase inhibitors
WO2004014880A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
DE10360835A1 (en) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg New bicyclic imidazole derivatives are dipeptidylpeptidase-IV inhibitors useful to treat e.g. arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis
ZA200609259B (en) * 2004-04-30 2008-07-30 Takeda Pharmaceutical Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
KR20070028536A (en) * 2004-06-15 2007-03-12 아스트라제네카 아베 Substituted quinazolones as anti-cancer agents
WO2008043087A2 (en) 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
WO2012052451A1 (en) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
CN103524431B (en) * 2013-09-24 2016-01-13 西安交通大学 3-benzyl-4-quianzolinones and synthetic method thereof and application
JO3512B1 (en) 2014-03-26 2020-07-05 Astex Therapeutics Ltd Quinoxaline derivatives useful as fgfr kinase modulators
LT3353164T (en) 2015-09-23 2022-01-25 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
JP6898919B2 (en) 2015-09-23 2021-07-07 ヤンセン ファーマシューティカ エヌ.ベー. New compound
FR3046793B1 (en) * 2016-01-14 2018-01-05 Les Laboratoires Servier NOVEL PHOSPHINAN DERIVATIVES AND AZAPHOSPHINANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002513394A (en) * 1996-12-17 2002-05-08 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー Fungicidal quinazolinones
PA8539401A1 (en) * 2001-02-14 2002-10-28 Warner Lambert Co QUINAZOLINAS AS INHIBITORS OF MMP-13
PA8539301A1 (en) * 2001-02-14 2002-09-30 Warner Lambert Co INHIBITORS OF THE METALOPROTEINASE OF THE MATRIX

Also Published As

Publication number Publication date
EP1492775A2 (en) 2005-01-05
TNSN04169A1 (en) 2007-03-12
PA8568501A1 (en) 2003-12-19
AU2002249275A1 (en) 2003-09-22
UY27700A1 (en) 2003-10-31
AU2003212307A1 (en) 2003-09-22
BR0308280A (en) 2004-12-28
AP2004003125A0 (en) 2004-09-30
CA2478706A1 (en) 2003-09-18
EA200401053A1 (en) 2005-04-28
PL372622A1 (en) 2005-07-25
WO2003076417A3 (en) 2003-11-13
ECSP045278A (en) 2004-10-26
IS7414A (en) 2004-08-19
NO20044041L (en) 2004-10-07
MXPA04008681A (en) 2004-12-06
WO2003076416A1 (en) 2003-09-18
WO2003076417A2 (en) 2003-09-18
OA12782A (en) 2006-07-10
SV2003001495A (en) 2003-11-04
JP2005526070A (en) 2005-09-02
IL163818A0 (en) 2005-12-18
PE20031018A1 (en) 2004-01-09
MA27183A1 (en) 2005-01-03
KR20040095270A (en) 2004-11-12
CN1738806A (en) 2006-02-22
AR039562A1 (en) 2005-02-23

Similar Documents

Publication Publication Date Title
CO5601020A2 (en) OX-AZABICICLIC COMPOUNDS
ECSP034730A (en) QUINAZOLINAS AS INHIBITORS OF MMP-13
CO5580747A2 (en) N-ADAMANTILMETILO DERIVATIVES AND INTERMEDIARIES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION
ES2120535T3 (en) CROSSLINKING AGENTS WITH CARBAMATE TRIFUNCTIONALITY.
CO5601018A2 (en) DERIVATIVES OF N-FENIL-2-PIRIMIDIN-AMINA
CO5560573A2 (en) ACTIVE DERIVATIVES OF AMINO-FTALAZINONA AS QUINASE INHIBITORS, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE338461T1 (en) PYRAZOLEPYRIMIDE INFUNGICIDES
AR049784A1 (en) SUBSTITUTED DERIVATIVES OF MORFOLINA AND TIOMORFOLINA
MY138145A (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
CO5690643A2 (en) TRIAZA-ESPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
PE20010211A1 (en) THIAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEIN KINASES
ES2193839B1 (en) NEW DERIVATIVES OF 6-PHENYLDIHYDROPIRROLPIRIMIDINDIONA.
NO20052976D0 (en) Phosphodiesterase-4 inhibitors.
ES2571779T3 (en) Nicotinamide-based kinase inhibitors
AR033379A1 (en) DIFENILUREA COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EE9800266A (en) Isoquinolines used as analgesics
ATE360045T1 (en) POLYCARBONATE COMPOSITIONS
HUP0402227A2 (en) Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase and pharmaceutical compositions containing the compounds
CO5690648A2 (en) NEW ANALOGS OF ACID 2´, 5´-OLIGOADENILICO
UA86013C2 (en) Aryl alkyl carbamate derivatives production and use thereof in therapy
PA8575001A1 (en) FLUOROBENZAMIDS AS MAOB INHIBITORS
ES2106185T3 (en) 3-CARBOXIESTEROIDS 17-BETA-SUBSTITUTED NOT SATURATED.
AR034585A1 (en) NEW SUBSTITUTED CYAN DIHYDROPIRIMIDINE COMPOUNDS AND THEIR USE FOR TREATMENT OF MATTERS
CO5550437A2 (en) CHEMICAL COMPOUNDS
PE20040750A1 (en) DERIVATIVES OF N- (1-ACETYLPIPERIDIN-4-IL) -4-BENZIDRIL-2-ISOPROPILPIPERAZIN-1-CARBOXAMIDE AS INHIBITORS OF 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3

Legal Events

Date Code Title Description
FA Application withdrawn